ConvaTec stock slips in FTSE 100 despite valuation upside signal

Published on 09/04/2026 at 22:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec stock is trading below a recent fair-value estimate, even as the wound-care specialist stays firmly in the FTSE 100. Fresh market data highlight the discount that could matter for long-term investors.

Moderne Medizintechnik-Reinraumfertigung mit Technikern an steriler Produktionslinie — ConvaTec Group Plc GB00BD3VFW73 zeigt moderne Medizintechnik-Fertigung mit sterilen Produktionslinien und Reinraumtechnikern, Illustration mit AI erstellt.

ConvaTec stock (ISIN GB00BD3VFW73) is trading at 228.20 pence as of September 4, 2026 on the London Stock Exchange, only 0.35% above the previous close and reflecting a calm session after a sharper move in the FTSE 100 the day before, according to market data compiled by Investing.com.

Price reaction and FTSE 100 context

Market data for September 3, 2026 show ConvaTec shares closing at 227.40 pence in London, down 6.20 pence from an earlier level of 233.60 pence and placing the stock among the biggest fallers in the FTSE 100 on that day, as highlighted in a market overview reported by Newswav.

A separate price snapshot for the ConvaTec listing under the ticker CTEC indicates an open at 227.60 pence and a previous close at 227.40 pence, corresponding to a market capitalization of 4.38 billion pounds as of September 4, 2026, according to the share-price overview provided by Hargreaves Lansdown.

Valuation gap versus fair-value estimate

Beyond the short-term price swings, the valuation story stands out: a recent analysis by Simply Wall St published on September 4, 2026 cites an estimated fair value for ConvaTec shares at 424 pence, compared with a current price level around 227.40 pence, implying a discount of roughly 46.4% in that framework.

The same analysis groups ConvaTec with other United Kingdom stocks screened for potential undervaluation, listing the company at a price of 2.274 pounds against an estimated intrinsic value of 4.24 pounds, which again signals a valuation gap of more than 40% based on that methodology.

Go deeper

More on ConvaTec stock and market context

For a broader view of ConvaTec stock and how it fits into the wider market environment, the company profile and additional news can be explored via the AD HOC NEWS topic page.

ConvaTec stock on ad-hoc-news.de Investor Relations

Products and business focus in advanced wound care

ConvaTec is known in the market for its advanced wound-care and ostomy-care solutions, a portfolio that places the group among key suppliers in the global chronic and acute wound-care segment and ties its long-term growth to trends such as aging populations and the rising prevalence of diabetes-related complications.

Stock level and investor perspective

With ConvaTec stock at 228.20 pence as of September 4, 2026 on the London Stock Exchange and a market capitalization around 4.38 billion pounds on the same date, the shares remain clearly within FTSE 100 territory while trading noticeably below the 424 pence fair-value estimate highlighted by Simply Wall St.